Free Trial

Sangamo Therapeutics (SGMO) Stock Forecast & Price Target

$0.40
+0.01 (+2.56%)
(As of 07/23/2024 ET)

Sangamo Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 6 Wall Street analysts who have issued ratings for Sangamo Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 3 have given a hold rating, and 3 have given a buy rating for SGMO.

Consensus Price Target

$5.67
1,312.08% Upside
High Forecast$10.00
Average Forecast$5.67
Low Forecast$1.00

According to the 6 analysts' twelve-month price targets for Sangamo Therapeutics, the average price target is $5.67. The highest price target for SGMO is $10.00, while the lowest price target for SGMO is $1.00. The average price target represents a forecasted upside of 1,312.08% from the current price of $0.40.

TypeCurrent Forecast
7/25/23 to 7/24/24
1 Month Ago
6/25/23 to 6/24/24
3 Months Ago
4/26/23 to 4/25/24
1 Year Ago
7/25/22 to 7/25/23
Consensus Rating
Moderate Buy
Moderate Buy
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$5.67$5.67$4.93$8.91
Forecasted Upside1,312.08% Upside576.73% Upside380.69% Upside285.62% Upside
Get Sangamo Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

SGMO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SGMO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Sangamo Therapeutics Stock vs. The Competition

TypeSangamo TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside1,312.08% Upside2,973.15% Upside9.74% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/15/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$5.00+755.42%
3/14/2024Royal Bank of Canada
4 of 5 stars
 Reiterated RatingSector Perform ➝ Sector Perform$2.00+145.10%
11/7/2023Truist Financial
1 of 5 stars
 Reiterated RatingBuy ➝ Hold
11/6/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Equal Weight$1.00+110.52%
8/11/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Argyrides
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$16.00 ➝ $10.00+825.92%
8/9/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$11.00 ➝ $9.00+689.47%
4/28/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$4.20 ➝ $3.90+178.57%
4/28/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$5.00 ➝ $1.50-6.25%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:07 AM ET.

SGMO Forecast - Frequently Asked Questions

What is Sangamo Therapeutics' forecast for 2024?

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Sangamo Therapeutics is $5.67, with a high forecast of $10.00 and a low forecast of $1.00.

Should I buy or sell Sangamo Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SGMO shares.

Does Sangamo Therapeutics's stock price have much upside?

According to analysts, Sangamo Therapeutics's stock has a predicted upside of 576.73% based on their 12-month stock forecasts.

What analysts cover Sangamo Therapeutics?

Sangamo Therapeutics has been rated by research analysts at HC Wainwright in the past 90 days.

Do Wall Street analysts like Sangamo Therapeutics more than its competitors?

Analysts like Sangamo Therapeutics less than other "medical" companies. The consensus rating score for Sangamo Therapeutics is 2.50 while the average consensus rating score for "medical" companies is 2.72. Learn more on how SGMO compares to other companies.


This page (NASDAQ:SGMO) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners